Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AX-024.HCl Safety and PK in Healthy Males
NCT02243683Phase 1Completed
- Sponsor
- Artax Biopharma
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AX-024 in autoimmune disease (2 cohorts), sponsored by Artax Biopharma. Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events at 7 days. Started Sep 2014; status: completed.
02
Drugs
AX-024
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT02243683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243683.